Evaluation with the DMB assay showed that TGFβ-treated AD-MSC in 3D culture had 48% more proteoglycan compared with AD-MSC in 3D culture alone (p < 0.05; Figure 3e). Here, TGFB1 is linked to Alzheimer disease.